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Anti-A and anti-B titers in pooled group O platelets are
comparable to apheresis platelets
Laura L. Cooling, Theresa A. Downs, Suzanne H. Butch, and Robertson D. Davenport
BACKGROUND: Although uncommon, acute hemolytic
transfusion reactions (AHTRs) have been reported after
transfusion of group O single-donor apheresis platelets
(SDPs) to group A, B, and AB recipients. Current
methods for identifying “high-titer” SDPs include tube
and gel methods. The risk of a high-titer unit is consid-
ered low with group O, poststorage, pooled platelet
concentrates (PPLTs); however, data regarding anti-A
and anti-B titers in PPLTs are lacking.
STUDY DESIGN AND METHODS: Anti-A and anti-B
titers were determined in 185 PPLTs by direct agglutina-
tion using manual gel and tube methods. PPLTs tested
included 124 group O PPLTs, 25 group A PPLTs, 26
group B PPLTs, and 10 PPLTs containing a mix of
either groups O plus A or groups O plus B (mixed
PPLTs). The reciprocal of the highest dilution giving
macroscopic agglutination was considered the aggluti-
nin titer.
RESULTS: Mean anti-A and anti-B titers in group O
PPLTs were, respectively, 16 and 8 by tube and 64 and
32 by gel (p < 0.0001). Gel titers were one to two dilu-
tions higher than tube and sensitive to reagent red cell
lots. With the use of at least 64 as a critical titer, 60
percent of group O PPLTs tested by gel would be con-
sidered high-titer. In mixed PPLTs, the addition of one
non-group O PLT significantly decreased or neutralized
the corresponding anti-A or anti-B (p < 0.0001).
CONCLUSION: Anti-A and anti-B titers in group O
PPLTs are comparable to those reported in group O
SDPs and significantly lower than titers reported in
AHTR. A critical direct agglutinin titer of 64 for identify-
ing high-titer units by gel is too low and should be
increased to 128 or higher.
A
lthough relatively rare, acute hemolytic trans-
fusion reactions (AHTRs) after out-of-group or
plasma-incompatible platelet (PLT) transfu-
sions continue to generate interest and discus-
sion, with approximately 40 reported cases worldwide.1-3
In nearly all instances, the implicated units were single-
donor apheresis platelets (SDPs) from donors possessing
unusually high-titer anti-A and anti-B agglutinins.1,2 At
present, the risk of an AHTR after an out-of-group PLT
transfusion are unknown; however, facility-specific rates
range from 1 in 2000 to less than 1 in 45,000.4-7 In the
United States, approximately 10 to 40 percent of all PLT
transfusions are plasma-incompatible with the intended
recipient.1,6,7
In a recent survey of US hospitals, most transfusion
services (83%) have policies to avoid or minimize expo-
sure of incompatible plasma to PLT recipients.2 Common
strategies include policies to provide only ABO type–
specific or plasma-compatible PLTs, volume reduction,
and limitations in the quantity of incompatible plasma
transfused over time.1,2 A small number of US institutions
(2%), as well as international blood centers, prospectively
screen group O SDPs for the presence of high-titer agglu-
tinins.1,2,8,9 These units are subsequently labeled as
“high-titer” and are reserved for transfusion to group O
recipients only. Group O SDPs are selectively screened
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because of the 1) plasma volume per donor (200 to
400 mL), 2) higher mean anti-A or anti-B titers in group
O donors, and 3) overwhelming prevalence of group
O SDPs among reported cases of PLT-associated
AHTRs.1,2
Two major challenges facing standardized, prospec-
tive screening are the absence of a recognized reference
method and critical end titer that will reasonably differ-
entiate safe from high-titer SDPs without significantly
hampering PLT availability to non-O patients.1 Methods
currently employed include tube saline agglutination,
with and without room temperature incubation or anti-
globulin testing, microcolumn agglutination (gel), auto-
mated microplate technology, and assays for in vitro
hemolysis.1,2 Critical titers range from more than 20 to
more than 500 and are determined locally based on assay
type.1 Recent studies with microcolumn or gel technol-
ogy have reported a reasonable correlation between gel
and routine tube titers, with minimal additional cost to a
SDP ($1.20 per SDP).9 In the latter study, between 28
and 39 percent of group O SDP units tested were consid-
ered high-titer based on either a critical direct agglutinin
titer of at least 64 (presumably immunoglobulin G [IgG])
or an indirect agglutinin titer of at least 256 (IgG) by
gel.
Unlike SDPs, group O pooled PLT concentrates
(PPLTs) are considered at minimal risk for precipitating
an AHTR after a single out-of-group transfusion. PPLTs
contain significantly less plasma per donor (50-60 mL),
which is subsequently diluted four- to sixfold in the final
pooled product. As a result, group O PPLTs should have a
lower mean anti-A or anti-B agglutinin titer and a lower
incidence of high-titer units than SDPs due to pooling of
multiple donor plasma. Despite the widespread use of
PPLTs for more than 40 years, little information is available
regarding mean anti-A or anti-B agglutinin titers in PPLTs.
In this study, we screened 185 PPLTs for anti-A and anti-B
by direct agglutination using both standard tube and
manual gel tests. Contrary to expectations, the distribu-
tion and mean agglutinin titers in PPLTs were comparable
or higher than those reported in other studies of group O
SDPs.9 In addition, our results suggest that published criti-
cal titers for identifying high-titer units by gel are too low




Leukoreduced, whole blood–derived PLT concentrates
(WBD-PLTs) were obtained from the Southeast Michigan
American Red Cross (Detroit, MI). For transfusion, 4 to
5 units of ABO type–specific, WBD-PLTs are pooled
(plasma transfer set, CharterMedical Ltd, Winston-Salem,
NC) immediately before transfusion by the hospital
transfusion service. On occasion, more than one ABO
type (group O plus A; group O plus B) may be pooled for
transfusion due to product shortages or to minimize
wastage. For transfusion purposes, PPLTs containing
at least one group O WBD-PLT unit are labeled and
dispensed as group O. On average, the University of
Michigan prepares and dispenses approximately 11,000
to 12,000 pools per year, representing a total of 55,000 to
60,000 WBD-PLTs.
Plasma samples for agglutinin titers were collected
from the tubing of freshly prepared PPLTs. Tubing was
stripped twice to assure that the contents were represen-
tative of the final pooled product and then heat-sealed to
obtain a 10- to 20-cm sterile segment for testing. All seg-
ments were stored at 4°C and were tested within 2 weeks of
collection. A clerical review was performed for all PPLTs
tested to confirm the content and ABO type of each WBD-
PLT unit in the pool. A total of 185 PPLTs were tested
including 124 group O, 25 group A, 26 group B, and 10
mixed PPLTs. Mixed PPLTs contained a mix of either group
O and group A (5 PPLTs) or group O and group B (5 PPLTs).
Approximately 95 percent (175/185) of PPLTs tested were
composed of 5 units of WBD-PLTs: 10 PPLTs (5.4%) con-
tained only 4 units of WBD-PLTs.
Anti-A and anti-B agglutinin titers
Serial twofold dilutions of plasma were prepared in 0.9
percent saline using a calibrated pipette. Samples were
tested, in parallel, for anti-A and anti-B by direct aggluti-
nation using both tube method and manual gel. Results
were reported as the reciprocal of the last dilution
demonstrating 1+ macroscopic agglutination. To avoid
interexaminer variation during testing, all testing by tube
method and manual gel were assigned and performed by
the same individual throughout the study. Over the course
of the study, two different lots of reagent RBCs were used
for tube and gel testing.
Testing by tube method was performed by adding
two drops of neat or diluted plasma and one drop of
commercially prepared 3 percent pooled A1 and B RBCs
(Lots A660 and A690, Ortho Clinical Diagnostics, Raritan,
NJ). Samples were centrifuged, without incubation, for
15 seconds (1290 relative centrifugal force). Results were
read and recorded immediately after centrifugation.10
Anti-A and anti-B agglutinin testing by manual gel
was performed per manufacturer’s instructions.11 Specifi-
cally, 50 mL of neat or diluted plasma and 50 mL of com-
mercially prepared A1 and B RBCs (0.8%; Lots 08A278 and
08A293, Ortho Diagnostics) were added to buffered gel
cards (Lot 012807004-02, MTS, Pompano Beach, FL) and
then centrifuged (10 min, 90 relative centrifugal force).
Results were read and recorded immediately after cen-
trifugation. In addition, all gel cards were photocopied for
permanent record keeping.
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PLT transfusion response
A retrospective chart review was performed for recipients
of high-titer and mixed PPLT units. High-titer units for
chart review were defined as an anti-A or anti-B titer of
at least 128 by gel. Recipients of high-titer units were
screened for evidence of hemolysis based on the recipi-
ents’ ABO type and pre- and posttransfusion hemoglobin,
lactate dehydrogenase, and bilirubin levels.
The PLT transfusion response was examined in recipi-
ents transfused with high-titer, ABO-incompatible PPLTs
and mixed PPLTs. Because information necessary to
calculate a corrected count increment
was not available for many patients, an
appropriate response to PLT transfusion
was defined as an increase in the post-
transfusion PLT count of 20 ¥ 109 per L
or greater at 1 to 4 hours after transfu-
sion. Patients showing a poor response
to a mixed PPLT transfusion were
reviewed for evidence of recent PLT
refractoriness in the 3 days before and
after the transfusion in question. The
latter included a review of all PLT trans-
fusions within a 7-day period, patient
diagnosis, ABO type, HLA antibody
screen, and the presence of pertinent
nonimmune factors (e.g., bleeding,
disseminated intravascular coagulation,
infection, splenomegaly) known to
adversely affect PLT transfusion.12,13
Statistical analysis
Results were plotted as the absolute
number and relative percentage (%) of
units for each end titer. Histograms and
t tests were performed with commercial
software (Kaleidograph, Synergy Soft-
ware, Reading, PA). Chi-square tests
were performed using software (EpiInfo,
Centers for Disease Control and Preven-
tion, Atlanta, GA).
RESULTS
Anti-A and anti-B agglutinin titers
in pooled group O PLTs by
tube method
A total of 124 group O PPLTs were tested
for anti-A and anti-B (Fig. 1A). By tube
method, the direct agglutinin titer for
anti-A and anti-B ranged from neat to 64
with mean titers of 16 and 8, respec-
tively. Only two group O PPLTs (1.6%)
had a titer of 64 or greater, which has been suggested as a
critical direct agglutinin titer by gel.9 Anti-A and anti-B
titers were also examined in 20 group O WBD-PLTs with
similar results (data not shown). A subanalysis of 5-unit
(n = 114) and 4-unit (n = 10) PPLTs found no significant
difference (p = 0.95).
Anti-A and anti-B agglutinin titers in pooled group
O PLTs by gel method
Anti-A and anti-B agglutinin titers were also determined,
in parallel, by manual gel as originally described by
Fig. 1. Anti-A (left column) and anti-B (right column) titers in group O PPLTs. (A)
Agglutinin titers by the tube method. (B) Agglutinin titers by the manual gel. Histo-
grams show the number of PPLT units for each end titer. The relative percentage of
units per end titer is denoted by the numbers atop each column. (C) Summary of
tube and gel testing for each PPLT tested. Note that anti-B titers were available in
only 123 of 124 group O PPLTs tested.
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Josephson and colleagues.9 As shown (Fig. 1B), anti-A
ranged from 4 to 512 with a mean direct agglutinin titer of
64. Anti-B ranged from 4 to 512 with a mean titer of 32. In
general, end titers were consistently one to two dilutions
higher by gel than tube method (Fig. 1C, p < 0.0001, paired
t test). With the use of at least 64 as a critical direct agglu-
tinin titer, approximately 60 percent of group O PPLTs
would be considered high-titer by gel.9 This is significantly
higher than the percentage of high-titer units identified by
tube (p < 0.00001, chi-square).
Anti-A titers in group B PPLTs
We also examined anti-A direct agglutinin titers in 26 group
B PPLTs (Fig. 2A).When compared to group O PPLTs, anti-A
titers tended to be lower in group B PPLTs by one to three
dilutions. Unlike group O PPLTs, there was no significant
difference in end titer between gel and tube methods
(p = 0.38). By both techniques, the mean anti-A titer was 8.
Anti-A titers were significantly decreased in group B PPLTs
relative to group O PPLTs by gel (8 vs. 64, p < 0.0001). No
group B PPLTs had an anti-A titer of at least 64.
Anti-B titers in group A PPLTs
Anti-B direct agglutinin titers were examined in 25 group
A PPLTs (Fig. 2B). There was, on average, a higher mean
titer by gel relative to tube (8 vs. 16, p < 0.0001). Overall,
the anti-B titers in group A PPLTs were roughly the same as
group O PPLTs by tube (p = 0.78). By gel, anti-B titers were
slightly decreased in group A PPLTs (p = 0.01). No group A
PPLTs had an anti-B titer of 64 or greater.
Anti-A and anti-B agglutinin titers in mixed PPLTs
Although it is general policy to pool and dispense type-
specific WBD-PLTs whenever possible, on occasion WBD-
PLTs of two ABO types were pooled (mixed PPLTs) for
transfusion due to product shortages. PPLTs containing at
least one group O WBD-PLT unit were labeled and dis-
pensed as group O. Over the 4-week course of the study, 10
units (7.5%, 10/134) were tested that were, in fact, a mix of
group O and non-O WBD-PLTs. These units were excluded
from the group O PPLT data and analyzed separately.
As shown in Table 1, all mixed PPLTs were composed
of either groups O plus A or groups O plus B, with the
number of non-O WBD-PLTs ranging
from 1 to 4 units. Interestingly, the addi-
tion of even one non-O WBD-PLT unit
(e.g., group B) markedly decreased or
neutralized the corresponding isoagglu-
tinin titer (e.g., anti-B). In 6 of 10
samples, no corresponding isohemag-
glutinin was identified by at least one
method, even after testing with neat,
undiluted plasma (Samples 86, 33, 128,
107, 113, and 118). When compared to
group O PPLTs, the decrease in titers
were highly significant (p < 0.0001). In
contrast, titers of the uninvolved,
remaining agglutinin (e.g., anti-A) were
unchanged and consistent with group O
PPLTs (p = 0.28-0.42).
We also examined the clinical trans-
fusion response to mixed PPLTs. Nine
units were transfused to leukemia
patients (9/10), including 7 patients
with a history of hematopoietic pro-
genitor cell transplant. In 9 patients, a
1- to 4-hour posttransfusion PLT count
was available for analysis. As shown in
Table 1, an appropriate increase in the
posttransfusion count (38.80 ¥ 109 
14.72 ¥ 109/L; range, 23.00 ¥ 109 to
55.00 ¥ 109) was observed in 5 of 9
patients, regardless of recipient ABO
type. Among the 4 patients with a
poor response to transfusion, 3 had
Fig. 2. Anti-A and anti-B agglutinin titers in group B and group A PPLTs by tube (left
column) and gel methods (right column). (A) Anti-A titers in group B PPLTs ( \\\ ). (B)
Anti-B titers in group A PPLTs ( /// ). For reference, anti-A and anti-B titers in group O
PPLTs () are also shown. Histograms denote the percentage of units at each end titer.
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laboratory evidence of clinical PLT refractoriness due to
nonimmune factors (sepsis, disseminated intravascular
coagulation, pulmonary hemorrhage).12,13 One group O
patient, however, had an isolated, profound transfusion
failure after transfusion of a mixed PPLT unit containing
predominantly group A WBD-PLTs (Sample 33). The latter
appears to be an example of ABO-associated PLT refrac-
toriness in a group O recipient.1,14-17 An anti-A titer of the
recipient was not performed.
Influence of reagent lots on end titers
The majority of PPLTs were tested with a single lot of com-
mercial reagent RBCs for tube and manual gel testing,
respectively. However, a subset of 19 group O PPLTs (15%)
were tested at a later date, using a different RBC lot. To
examine whether different reagent lots can influence end
titer, we compared the mean end titer and distribution for
each lot tested. Overall, there was no significant difference
in mean titer between lots by tube testing. There was,
however, a difference in testing by gel. Among the 19 PPLTs
tested by gel using a different RBC reagent lot, the mean
anti-A and anti-B titers were both lower (mean titer, 16;
range, 4 to 128) than the population mean. Only 3 units
(16%) had a titer of 64 or greater (chi-square, p < 0.0001).
An apparent decrease in gel titers was also noted
when comparing tube and gel testing in paired samples
(Fig. 1C). In the vast majority of group O samples tested
(103/105, 98%; RBC Lot 08A278), gel titers were always
higher by at least one dilution over tube testing. In con-
trast, gel titers were the same or decreased relative to tube
titers in 8 of 19 (42%) samples tested with a different lot of
0.8 percent A1 RBCs (Lot 08A293). These results suggest
that anti-A and anti-B titers by gel may be more sensitive
to changes in reagent lots than anticipated.
Review of out-of-group PLT transfusions
A retrospective review was performed for all group O
PPLTs with an anti-A or anti-B titer of 128 or greater by gel.
A critical titer of 128 was chosen based on a review of
European institutions, which use a critical titer between
100 to 200 for screening group O donors.1,8 Among group O
PPLTs, 27 or 22 percent had a direct agglutinin titer of at
least 128. As stated earlier, more than 60 percent of all
group O PPLTs would be considered high-titer using a
critical titer of 64 or greater as recommended by Joseph-
son and colleagues.9
Among 27 high-titer group O PPLTs, 25 (93%) were
transfused to group O recipients. Two out-of-group trans-
fusions (anti-A gel titer, 128) were transfused to group A
recipients. There were no reports of transfusion reactions
or laboratory evidence of hemolysis after transfusion.
Both patients had an appropriate clinical response to
transfusion based on a 1- to 4-hour posttransfusion PLT
count (data not shown).
Comparison of anti-A and anti-B titers in group O
PPLTs and AHTRs
To evaluate the potential risk of AHTRs due to group O
PPLTs, we compared ABO titers in our group O PPLTs with
published cases of AHTR (Fig. 3). Published cases were
limited to AHTR after an out-of-group PLT transfusion, in
which ABO titers were performed by direct agglutination
using a standard tube method. A total of 23 published
cases were identified for comparison.1-3 All cases selected
involved transfusion of group O PLTs to an A or AB recipi-
ent. Results are presented as the percentage (%) of units
for each end titer (anti-A only). In PLT-associated AHTRs,
anti-A titers ranged from 32 to 16,000, with a mean titer of
512. In general, anti-A titers in group O PPLTs were signifi-
cantly lower than those associated with AHTR.
DISCUSSION
In the past decade, there have been several reports of
AHTR after transfusion of group O SDPs to group A, B, and
TABLE 1. Anti-A and anti-B agglutinin titer and transfusion response in mixed PPLTs
Sample
Composition of mixed PPLT units* Agglutinin titer Transfusion response
Group O Group A Group B
Anti-A Anti-B
Recipient ABO Clinical response† PLT refractory‡Tube Gel Tube Gel
6 4 1 1 2 8 16 O Yes No
45 3 2 1 2 2 8 O No Yes
4 2 3 2 8 8 32 A No Yes
86 2 3 0 1 2 16 A Yes No
33 1 4 0 0 8 32 O No No
11 4 1 8 64 1 4 O NA§ Yes
128 4 1 16 16 0 1 O No Yes
107 3 2 8 32 0 0 O Yes No
113 3 2 16 32 0 2 A Yes No
118 2 3 16 32 0 0 A Yes No
* PPLTs containing a mix of group O and either group A or group B WBD-PLTs.
† Increase in PLT count of 20 ¥ 109 per L or greater at 1 to 4 hours after transfusion.
‡ Clinical or laboratory evidence of PLT refractoriness in the 3 days before and 3 days after transfusion of a mixed PPLTs.
§ NA = not available.
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AB recipients.1-3,5-7 In nearly all cases, laboratory investiga-
tions revealed unusually high-titer anti-A or anti-B agglu-
tinins in the donor. To reduce the risk of AHTR due to
out-of-group SDP transfusions, several blood centers in
Europe and the United States prospectively screen group
O SDPs for high-titer donors.1,2,8,9 A variety of different
testing platforms (tube, gel, microplate) and endpoints
(direct agglutination, indirect antiglobulin test, hemoly-
sis) are currently employed, with 3 to 39 percent of units
testing as high-titer in recent studies.1
In 2004, Josephson and colleagues9 at Emory reported
their experience using manual gel for screening group O
SDPs. The gel method offers several potential advantages
over tube testing including standardized pipetting of
reagents and a stable agglutination reaction that may be
reviewed and photographed or photocopied for record
keeping.18,19 In their initial trial, the authors screened 100
group O SDPs for anti-A/AB over a period of 3 to 4 months,
starting at an initial dilution of 32. In their experience, 72
percent of units had a direct agglutinin titer of less than 64,
with a mean titer of 32 by gel. In 10 paired samples, gel
titers were equivalent or one to two dilutions lower than
tube titers. Equivalent or weaker agglutination with gel
has been noted by others, particularly for anti-B.18,19 Based
on their experience, the authors chose critical end titers of
at least 64 for direct agglutination and at least 256 for
indirect agglutination to identify high-titer units. In their
pilot study, 28 percent of group O SDPs were classified as
high-titer based on direct agglutination.
We sought to duplicate the findings of Josephson
and coworkers with group O, poststorage PPLTs. We
anticipated that group O PPLTs would have a lower mean
titer than that reported for group O SDPs with no high-
titer units. Anti-A and anti-B agglutinin titers were deter-
mined, in parallel, by tube and gel methods in 185 PPLTs,
including 124 group O PPLTs. Overall, the distribution and
mean direct agglutinin titer (8 to 16) by tube method were
consistent with recent studies in industrialized coun-
tries20,21 although significantly lower than older, frequently
cited papers from the 1940s.22-24 Only 50 years ago, 13 to 65
percent of group O donors were considered “dangerous
donors” based on tube titers of 256 or greater, with most
donors (55%-90%) possessing titers of 64 or greater.22-24
The dramatic decrease in isoagglutinin titers observed in
modern societies has been attributed to an increase in
processed food.20
Relative to tube titers, direct agglutinin titers by gel
were consistently higher by one to two dilutions in the
majority of PPLTs tested. The exceptions were group B
PPLTs and a subset of group O donors tested with a differ-
ent lot of A1 test cells. In these samples, equivalent anti-A
titers were observed by tube and gel in 25 to 42 percent of
units. Overall, the mean direct agglutinin titers in group O
PPLTs were the same or higher than those reported for
group O SDPs.9 More surprising, the percentage of group
O PPLTs with direct agglutinin titers of at least 64 was
significantly higher than group O SDP historical controls
(60% vs. 28%, p = 0.00002). Unfortunately, we were unable
to perform parallel testing in both PPLTs and SDPs due to
the low numbers of SDPs available in our facility (10-20
per month).
Variation in commercial reagent RBCs may account
for the unexpected number of high-titer units observed in
our study. Although we used the same manufacturer as
Josephson and colleagues for gel cards and reagent RBCs
(0.8% suspension), our own data suggest that gel titers
may be more sensitive than tube titers to different reagent
RBC lots. Specifically, we noted a two- to fourfold differ-
ence in mean anti-A titers (16 to 64) between two-reagent
RBC lots. This difference is comparable to that observed
between our study and that by Josephson and colleagues,
in which mean anti-A titers differed by a single dilution (64
vs. 32). It is interesting to note that the percentage of high-
titer units in our study decreased from 60 to 22 percent by
simply increasing the critical titer by one dilution (128).
Our results indicate that variations in 0.8 percent RBCs
can profoundly influence the percentage of units classi-
fied as high-titer at a direct agglutinin titer of 64 or greater.
In addition, we noted that direct agglutinin titers by
gel tended to be higher than tube, which is contrary to the
findings of Josephson and colleagues. This may reflect
differences in RBC reagents, method, and number of
samples tested by tube method between the two studies.
Although we performed parallel testing in all samples,
Josephson and coworkers9 performed gel and tube titers
in only a small subset of samples (n = 10), which may have
Fig. 3. Comparison of anti-A titers in group O PPLTs and PLT-
associated AHTR. Anti-A tube titer reported in 23 published
cases of AHTR after transfusion of group O PLTs ( ). As refer-
ence, anti-A tube titers in group O PPLTs are also shown ().
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been insufficient to detect a difference between the two
methods. In addition, the authors did not use commercial
pooled reagent RBCs for tube testing but prepared their
own 3 percent A1 RBCs, suggesting the use of a single A1
donor for testing. It has long been recognized that isoag-
glutinin titers can “vary with the same serum using differ-
ent cells”25 due, in part, to an almost 30 percent variation
in the number of A antigen sites on A1 RBCs.26 To minimize
donor-specific variation, reagent manufacturers pool
RBCs from two donors when preparing A1 and B reagent
RBCs (personal communication, Ortho Clinical Diag-
nositics, Raritan, NJ). Finally, we performed tube testing
by a standard “immediate-spin” technique whereas
Josephson and colleagues included a 15-minute room
temperature incubation before centrifugation, an estab-
lished enhancement technique for isoagglutinin testing
by tube.9,10
In addition to group O PPLTs, we serendipitously
tested 10 mixed PPLTs, containing a mix of group O and
either group A or group B WBD-PLTs. In general, the pres-
ence of even one non-O WBD-PLT unit significantly
decreased or completely neutralized the corresponding
agglutinin in group O plasma. We hypothesize that ABO-
active substances present in plasma, and on PLTs,1,14 can
bind and neutralize anti-A and anti-B agglutinins in group
O, mixed PPLTs. The ability of group A, B, and AB plasma to
neutralize anti-A and anti-B agglutinins is well established
and was the basis for “conditioned group O blood” and
“universal plasma” in the early days of transfusion medi-
cine.25,27 Pooled plasma preparations containing 5 to 50
units of plasma, regardless of donor ABO type, were trans-
fused to adult trauma and surgical patients with few
reported hemolytic transfusion reactions.25,28 Modern
“pooled” universal plasma formulations (Uniplas, Octap-
harma Pharmazeutika, Austria; Bioplasma FDP, National
Bioproducts Institute, Pinetown, South Africa) exist and
contain a defined mixture of group A, B, AB, and O donor
plasma with isohemagglutinin titers of less than 8 to less
than 32 and acceptable transfusion safety.29-31 Although
extremely limited, our data suggest that mixed PPLTs, con-
taining one WBD-PLT unit of recipient ABO type, could
provide an additional layer of safety when out-of-group
transfusion is unavoidable.
At present, poolingWBD-PLTs of different ABO types is
generally discouraged due to possible immune complex
formation, PLT activation, labeling requirements, and
potential negative impact on the posttransfusion
response.32-34 In times of shortages, however, it is some-
times necessary to pool WBD-PLTs of more than one ABO
type. Recently, Sweeney and colleagues35 examined the in
vitro effects of mixing group O and A WBD-PLTs using
prestorage pooled PLTs (Acrodose, Pall Medical, Covina,
CA). Over 5 days of storage, there was a small increase in
P-selectin expression and PLT microaggregates in mixed
PPLTs; however, there were no significant changes in PLT
count, hypotonic shock response, shape change, glucose,
lactate, pH, inflammatory cytokines, or coagulation
factors. Although controlled clinical trials are lacking,
anecdotal evidence suggests no increase in reported
adverse reactions after transfusion of mixed PPLTs.36
Among our patients, most patients had an appropriate
increase in PLT count with no reported adverse events. The
single exception was a group O patient with evidence of
ABO-incompatible PLT refractoriness after transfusion of a
mixed PPLTs containing 4 units of group A WBD-PLTs.14-17
In summary, our findings show that group O PPLTs
have anti-A and anti-B direct agglutinin titers comparable
to those recently reported in group O SDPs9 using both
tube and gel methods. In addition, anti-A and anti-B
agglutinin titers by gel are often higher than routine tube
methods and may be particularly sensitive to changes in
reagent RBC lots. Based on our data, we believe that a
direct agglutinin titer of 64 or greater is too conservative
and overly sensitive to reagent variability and could lead
to substantial numbers of SDPs being unnecessarily
labeled as high-titer.
These results also underscore the difficulty in estab-
lishing a reliable method and critical titer to identify
high-titer PLTs. Ideally, the critical titer should identify
units with clinically significant, high-titer anti-A or anti-B
agglutinins with a reasonable risk of precipitating
hemolysis after an out-of-group transfusion. Based on
clinical reports, we have shown that 80 percent of all
AHTRs had direct agglutinin titers of more than 128.
Based on the literature, we recommend increasing the
critical direct agglutinin titer of 128 to 200 when using
gel, which tended to have higher-end titers over the
immediate-spin tube method in our experience. This
would also be consistent with practices in the United
States, England, and Sweden, which use direct agglutinin
titers of more than 100 to more than 200 to identify high-
titer units, with approximately 3 to 5 percent of donors
testing as high-titer. The addition of screening with IgG
gel cards may increase the number of high-titer SDPs
identified by up to 10 percent, but may catch rare units
with isolated elevated IgG titers missed by direct
agglutination.9,37
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